Literature DB >> 19451289

Efficacy of liposomal amphotericin B combined with gamma interferon or granulocyte-macrophage colony-stimulating factor for treatment of systemic zygomycosis in mice.

M Mar Rodríguez1, Enrique Calvo, Marçal Mariné, F Javier Pastor, Joan Fernandez-Ballart, Josep Guarro.   

Abstract

Granulocyte-macrophage colony-stimulating factor enhanced the efficacy of liposomal amphotericin B (LAMB) in a murine model of disseminated infection by Rhizopus oryzae, significantly prolonging survival and reducing tissue burden. The use of gamma interferon (IFN-gamma) alone was ineffective, and IFN-gamma combined with LAMB did not improve the results obtained with LAMB alone.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19451289      PMCID： PMC2715637          DOI： 10.1128/AAC.00456-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  19 in total

1.  Posaconazole as salvage therapy for zygomycosis.

Authors:  R N Greenberg; K Mullane; J-A H van Burik; I Raad; M J Abzug; G Anstead; R Herbrecht; A Langston; K A Marr; G Schiller; M Schuster; J R Wingard; C E Gonzalez; S G Revankar; G Corcoran; R J Kryscio; R Hare
Journal:  Antimicrob Agents Chemother       Date:  2006-01       Impact factor: 5.191

2.  Resolution of rhinocerebral zygomycosis associated with adjuvant administration of granulocyte-macrophage colony-stimulating factor.

Authors:  J B Garcia-Diaz; L Palau; G A Pankey
Journal:  Clin Infect Dis       Date:  2001-05-07       Impact factor: 9.079

3.  Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice.

Authors:  K V Clemons; J E Lutz; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Recombinant murine granulocyte-macrophage colony-stimulating factor modulates the course of pulmonary histoplasmosis in immunocompetent and immunodeficient mice.

Authors:  G S Deepe; R Gibbons
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

5.  Interferon- gamma and granulocyte-macrophage colony-stimulating factor augment the activity of polymorphonuclear leukocytes against medically important zygomycetes.

Authors:  Cristina Gil-Lamaignere; Maria Simitsopoulou; Emmanuel Roilides; Avgi Maloukou; Richard M Winn; Thomas J Walsh
Journal:  J Infect Dis       Date:  2005-02-25       Impact factor: 5.226

6.  Posaconazole combined with amphotericin B, an effective therapy for a murine disseminated infection caused by Rhizopus oryzae.

Authors:  M Mar Rodríguez; Carolina Serena; Marçal Mariné; F Javier Pastor; Josep Guarro
Journal:  Antimicrob Agents Chemother       Date:  2008-08-11       Impact factor: 5.191

Review 7.  Difficulties with fungal infections in acute myelogenous leukemia patients: immune enhancement strategies.

Authors:  Amar Safdar
Journal:  Oncologist       Date:  2007

Review 8.  Treatment of zygomycosis: current and new options.

Authors:  Thomas R Rogers
Journal:  J Antimicrob Chemother       Date:  2008-01       Impact factor: 5.790

9.  Posaconazole mono- or combination therapy for treatment of murine zygomycosis.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Julie A Schwartz; John E Edwards; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2008-10-20       Impact factor: 5.191

10.  Comparison of lipid amphotericin B preparations in treating murine zygomycosis.

Authors:  Ashraf S Ibrahim; Teclegiorgis Gebremariam; Mohamed I Husseiny; David A Stevens; Yue Fu; John E Edwards; Brad Spellberg
Journal:  Antimicrob Agents Chemother       Date:  2008-01-28       Impact factor: 5.191
View more
  3 in total

1.  Combination therapy for mucormycosis: why, what, and how?

Authors:  Brad Spellberg; Ashraf Ibrahim; Emmanuel Roilides; Russel E Lewis; Olivier Lortholary; George Petrikkos; Dimitrios P Kontoyiannis; Thomas J Walsh
Journal:  Clin Infect Dis       Date:  2012-02       Impact factor: 9.079

2.  Granulocyte macrophage colony-stimulating factor in 66 patients with myeloid or lymphoid neoplasms and recipients of hematopoietic stem cell transplantation with invasive fungal disease.

Authors:  Amar Safdar; Gilhen Rodriguez; Jorge Zuniga; Fadi Al Akhrass; Georgia Georgescu; Anupam Pande
Journal:  Acta Haematol       Date:  2012-10-02       Impact factor: 2.195

Review 3.  The mucormycete-host interface.

Authors:  Ashraf S Ibrahim; Kerstin Voelz
Journal:  Curr Opin Microbiol       Date:  2017-11-04       Impact factor: 7.934
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.